Whether your personal interests are in supporting innovation, bringing lifesaving biomedical products to patients, training the next generation of biomedical leaders or fueling our economy, the Center for Biotechnology provides a vehicle to accomplish great things. Things that matter. Things that change, and save, lives.
Your involvement is an essential part of our future. Please consider a gift to the Center for Biotechnology which will help fuel innovation by ensuring that lifesaving technologies make it out of research labs and into the hands of patients.
Give to the Center for Biotechnology online through the Stony Brook Foundation. Contributions can be made to our Fund for Excellence. More information about donating through the Stony Brook Foundation can be found here.
CFB Director Elected Fellow, National Academy of Inventors (NAI)
December 15, 2017
Clinton Rubin, PhD, Director of the Center for Biotechnology and Distinguished Professor of Biomedical Engineering at Stony Brook University has been elected as a Fellow of the National Academy of Inventors (NAI). According to the NAI, election as an NAI Fellow is a high honor bestowed upon academic innovators and inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions and innovations that have made a tangible impact on quality of life, economic development, and the welfare of society. Dr. Rubin and fellow SBU Distinguished Professor Dr. Arie Kaufman will be inducted as NAI Fellows during its 2018 national meeting in Washington, DC, on April 5.
With the election of the 2017 class there are now 912 NAI Fellows, representing over 250 research universities and governmental and non-profit research institutes. The 2017 Fellows are named inventors on nearly 6,000 issued U.S. patents, bringing the collective patents held by all NAI Fellows to more than 32,000 issued U.S. patents.
Professor Rubin, founding chair of Stony Brook’s Department of Biomedical Engineering, pioneered research in understanding the role of mechanical signals in the musculoskeletal system and has patented technology that includes use of low frequency mechanical signals (vibrations) to combat disease like osteoporosis and obesity.
More on Dr. Rubin’s election as an NAI Fellow can be access here and here.
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
[post_title] => Center for Biotechnology Announces Redesignation as New York State Center for Advanced Technology
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => redesignation2025
[to_ping] =>
[pinged] =>
[post_modified] => 2025-07-21 14:51:44
[post_modified_gmt] => 2025-07-21 18:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4906
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4488
[post_author] => 4
[post_date] => 2024-10-24 10:45:00
[post_date_gmt] => 2024-10-24 14:45:00
[post_content] =>
Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.
[post_excerpt] =>
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park
[to_ping] =>
[pinged] =>
[post_modified] => 2025-02-26 16:35:20
[post_modified_gmt] => 2025-02-26 21:35:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4488
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4285
[post_author] => 4
[post_date] => 2023-09-11 12:13:16
[post_date_gmt] => 2023-09-11 16:13:16
[post_content] =>
Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”
The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.
Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include: – Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital – Doreen Swift, Senior Director, Embedded Software Engineering, IPS – Michael R. Bielski, President, DevTech Partners – Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University – Paul Schwartz, Director, Advanced Propulsion Technologies
This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.
[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23
[post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23
[to_ping] =>
[pinged] =>
[post_modified] => 2024-08-22 11:31:25
[post_modified_gmt] => 2024-08-22 15:31:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://centerforbiotechnology.org/?p=4285
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 4559
[post_author] => 3
[post_date] => 2025-01-14 09:29:08
[post_date_gmt] => 2025-01-14 14:29:08
[post_content] =>
CNY Biotech Accelerator’s (CNYBAC) Medical Device Innovation Challenge (MDIC) is a 6-month virtual program mentoring selected early-to-mid stage start-up companies each year. The MDIC serves as a complementary and collaborative initiative to assist teams in preparation for incubation programs, expand their innovation ecosystem, and assess strategic planning by providing mentorship, resources, funding/pitch opportunities, and connections. Teams must be US-based and commercializing a medical device per FDA definition.
The initial MDIC Application is accepted January through March 15 each year. Those that fully complete the initial application are sent an Innovation Law Center Supplemental Application to be completed by March 31. Only those applicants that fill out both forms will move on to the selection process.
CNYBAC Medical Device Innovation Challenge (MDIC) Two-step Application Process: Step 1: Confirm eligibility Step 2: Complete Innovation Law Center (ILC) Application Review Form
If you meet the eligibility, complete an MDIC Application and return by March 15 to durdonk@upstate.edu.
Still time to register! Registration for the 8th annual Hack@CEWIT will close March 1 at 3pm.
Join hundreds of student hackers at the Center of Excellence in Wireless and Information Technology (CEWIT) for a 40-hour hackathon to learn new skills, make new connections, develop innovative ideas and compete for amazing prizes.
CEWIT will open its doors for the event at 5pm today. Do not miss your opportunity to Unleash Innovation and Transform Tomorrow
All participants must reside in the U.S and be currently registered in a college/university as an undergraduate, graduate, or PhD student.
The Redesignation brings $10 million in funding to drive innovation, company formation, and economic growth.
The Center for Biotechnology (CFB) has announced its re-designated as a Center for Advanced Technology (CAT) by Empire State Development's Division of Science, Technology and Innovation (NYSTAR), a recognition that comes with $1 million in annual funding over the next ten years. The $10 million commitment underscores the CFB’s leadership in accelerating life science innovation, supporting early-stage technology development, and fueling economic growth through start-up formation and industry partnerships.
“The Center for Biotechnology has served as a critical bridge between academic research and commercial success,” said Dr. Clinton Rubin, Director of the Center for Biotechnology. “This re-designation ensures we can continue to expand our impact, helping innovators bring breakthrough technology to market and strengthening New York’s position as a leader in the bioscience industry.”
Empire State Development President, CEO and Commissioner Hope Knight said, “NYSTAR’s Centers for Advanced Technology are vital to our strategic efforts to grow New York’s economy and the state’s greater innovation ecosystem. By investing in the industries of tomorrow, New Yorkers benefit today through dynamic partnerships that help to create new jobs, generate more revenues, and encourage more companies to establish a footprint in communities all throughout the state.”
The Center for Biotechnology is located on the campus of Stony Brook University (SBU), the flagship research institution within the prestigious State University of New York (SUNY) system. Stony Brook University is recognized as a national and global leader in life sciences research, biomedical innovation, and clinical care. Situated on Long Island, New York, Stony Brook has built a formidable reputation as a hub for cutting-edge scientific discovery and translational medicine. The Center for Biotechnology builds upon these strengths by providing cutting-edge programming and competitive financial support to advance biomedical innovation and emerging company growth.
“We are excited to build upon the successful foundation of strong entrepreneurial networks, infrastructure, and programming that we have built over the last four decades” said Dr. Diane Fabel, Chief Operating Officer at the Center for Biotechnology. “The impacts we have had during our last designation period include over $1B in total economic impact with more than 1000 jobs created, and driving more than $315M in follow-on funding. We are excited to see those numbers continue to grow when we celebrate fifty years of hard work at the end of this redesignation period”.
As part of the New York State CAT program, the CFB will continue to work with emerging and established companies across the state to de-risk early-stage technologies, advance both technology and company value, foster public-private collaboration, and provide critical infrastructure for the region’s growing life science ecosystem. Additionally, the CFB team will continue its efforts to develop a life sciences workforce to support the region's bio-innovation economy with a specific emphasis on sectors deemed important to the NYS economy.
